Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study

Burge P S; Calverley P M A; Jones P W; Spencer S; Anderson J A
August 2003
Thorax;Aug2003, Vol. 58 Issue 8, p654
Academic Journal
BACKGROUND: A trial of corticosteroids has been recommended for all patients with chronic obstructive pulmonary disease (COPD), with the subsequent "response" determining the treatment selected. This approach assumes that patients can be reliably divided into responder and non-responder groups. We have assessed whether such a separation is statistically valid, which factors influence the change in forced expiratory volume in 1 second (FEV(1)) after prednisolone, and whether the prednisolone response predicts 3 year changes in FEV(1), health status, or number of exacerbations during placebo or fluticasone propionate treatment. METHODS: Oral prednisolone 0.6 mg/kg was given for 14 days to 524 patients with COPD before randomised treatment for 3 years with fluticasone propionate or placebo. Factors relating to change in FEV(1) after prednisolone were investigated using multiple regression. The response to prednisolone was entered into separate mixed effects models of decline in FEV(1) and health status during the 3 years of the study. RESULTS: The post-bronchodilator FEV(1) increased by a mean 60 ml (CI 46 to 74) after prednisolone with a wide unimodal distribution. Current smoking was the factor most strongly associated with the change in FEV(1) after prednisolone, with an increase of 35 ml in current smokers and 74 ml in confirmed ex-smokers (p<0.001). There was no relationship between the change in FEV(1) after prednisolone and the response to inhaled bronchodilators, baseline FEV(1), atopic status, age, or sex. The response to prednisolone, however expressed, was unrelated to the subsequent change in FEV(1) over the following 3 years on either placebo or fluticasone propionate. Regression to the mean effects explained much of the apparent prednisolone response. The significant effect of treatment on decline in health status was not predicted by the prednisolone response. CONCLUSION: Patients with COPD cannot be separated into discrete groups of corticosteroid responders and non-responders. Current smoking reduces the FEV(1) response to prednisolone. Prednisolone testing is an unreliable predictor of the benefit from inhaled fluticasone propionate in individual patients.


Related Articles

  • Quality-of-life and asthma control with low-dose inhaled corticosteroids. Roberts, June; Williams, Angela // British Journal of Nursing;10/28/2004, Vol. 13 Issue 19, p1124 

    Guidelines are available to assist healthcare professionals in the appropriate management of patients with asthma, a highly prevalent and debilitating disease. Despite these guidelines many patients are still not being optimally treated, often resulting in poor asthma control and consequent...

  • Real-Life GOLD 2011 Implementation: The Management of COPD Lacks Correct Classification and Adequate Treatment. Koblizek, Vladimir; Pecen, Ladislav; Zatloukal, Jaromir; Kocianova, Jana; Plutinsky, Marek; Kolek, Vitezslav; Novotna, Barbora; Kocova, Eva; Pracharova, Sarka; Tichopad, Ales // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Chronic obstructive pulmonary disease (COPD) is a serious, yet preventable and treatable, disease. The success of its treatment relies largely on the proper implementation of recommendations, such as the recently released Global Strategy for Diagnosis, Management, and Prevention of COPD (GOLD...

  • Healthcare utilisation and costs associated with adding montelukast to current therapy in patients with mild to moderate asthma and co-morbid allergic rhinitis: PRAACTICAL study. dal Negro, Roberto; Piskorz, Peter; Vives, Roberto; Guilera, Magda; Kocevar, Vasilisa Sazonov; Badia, Xavier; Sazonov Kocevar, Vasilisa // PharmacoEconomics;2007, Vol. 25 Issue 8, p665 

    Objective: To evaluate the healthcare resource use and costs associated with adding montelukast to therapy in patients with mild to moderate persistent asthma and co-morbid seasonal allergic rhinitis whose asthma is inadequately controlled by their current asthma...

  • Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease. Bonay, M.; Bancal, C.; Crestani, B.; Bonay, Marcel; Bancal, Catherine; Crestani, Bruno // Drug Safety;2002, Vol. 25 Issue 1, p57 

    Inhaled corticosteroids have a proven benefit in the management of asthma, but until recently, their efficacy in non-asthmatic, smoking-related chronic obstructive pulmonary disease (COPD) was not evidence-based. Airway inflammation in COPD differs from inflammation in asthma. Some studies have...

  • Inhaled corticosteroids and COPD exacerbations. Kuritzky, Louis // Internal Medicine Alert;3/29/2010, Vol. 32 Issue 6, p48 

    The article reports on the effectiveness of inhaled corticosteroids (ICS) in treating acute exacerbations of chronic obstructive pulmonary disease (AC-COPD).

  • High-dose steroids cut COPD deaths. Polak, Monika // GP: General Practitioner;2/3/2003, p17 

    Reports on a study published in the 'European Respiratory Journal' stating that treating patients with medium and high dose of inhaled corticosteroids after discharge from hospital from chronic obstructive pulmonary disease (COPD) have a lower risk of deaths. Doses of steroids for patients with...

  • Discontinuing Inhaled Steroids in COPD Patients. Carter, Chuck // American Family Physician;4/15/2003, Vol. 67 Issue 8, p1803 

    Discusses the study 'Effect of Discontinuation of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease,' by P. Van der Valk et al., from the November 15, 2002 issue of the 'American Journal of Respiratory and Critical Care Medicine.'

  • Combination therapy in COPD benefits patients.  // Practice Nurse;3/14/2003, Vol. 25 Issue 5, p19 

    Presents a study about the significance of combining an inhaled long-acting beta[sub2]-agonist with an inhaled corticosteroid to patients with chronic obstructive pulmonary disease. Reduction in exacerbations in the combined group compared with reductions in the monotherapy groups; Difference...

  • Q/What are the benefits and risks of inhaled corticosteroids for COPD? Hamilton, Tanya; Miller, John B.; Vincent, E. Chris; St. Anna, Leilani; Guthmann, Richard // Journal of Family Practice;May2014, Vol. 63 Issue 5, p276 

    The article provides an answer to a question regarding the benefits and risks of inhaled corticosteroids for chronic obstructive pulmonary disease (COPD).


Read the Article


Sign out of this library

Other Topics